Published in Medical Devices and Surgical Technology Week, May 13th, 2007
The findings suggest that a drug that can block this “survival protein” might on its own be an effective therapy.
But such a drug used in combination with several existing drugs might also offer an effective one-two punch against drug-resistant forms of chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). The two forms of cancer kill about 20,500 Americans yearly.
The survival protein is called Mcl1. It usually helps keep normal cells healthy and is involved in the development...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices and Surgical Technology Week